Tabernanthe iboga
1Provenance card
the boundary, as counts
Sources
4233 with DOI
4 strong · 33 moderate · 5 weak
Compilations
12026-05-14T10:29:32.324Z
pipeline-v5 · prompt hash not recorded — run predates 2026-09
Decisions
23last ruled 2026-06-04
0 awaiting a ruling
Issued documents
42026-10-19T20:34:05.654Z
notice · info card · emergency
Searches
250 with no results
queries and counts on the build
Claims checked
8921 supported
21 supported · 68 not
Correspondence
0received
consent field ships in Phase 4
Edges
278
derivations recorded for this entity
Complete over 42 sources, 1 compilation, and 23 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/tabernanthe-iboga/archive
Timeline
what happened, newest first — claims, searches and artifacts stay inside Build
- 2026-10-19issueIssued info_card
- 2026-09-07srcInfluence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers
- 2026-09-07srcIdentifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies
- 2026-09-07srcVoacangine/coronaridine hydroxylases catalyze C19-hydroxylation in iboga alkaloid synthesis
- 2026-09-07srchERG Blockade by Iboga Alkaloids
- 2026-09-07srcThe Cultural Importance of Plants in Western African Religions
- 2026-09-07srcNeural Correlates of Ibogaine: Evidence From Functional Neuroimaging of Military Veterans
- 2026-09-07srcIncreased cortical thickness and decreased brain age among special operations veterans with blast TBI after a magnesium-ibogaine protocol
- 2026-09-07srcMystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans
- 2026-09-07srcA systematic literature review of clinical trials and therapeutic applications of ibogaine
- 2026-09-07srcNeurorestorative properties of ibogaine: linking multi-receptor affinities to remyelination and metabolic restoration
- 2026-09-07srcWhat We Have Gained from Ibogaine: alpha3beta4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders
- 2026-09-07srcDeciphering Ibogaine's Matrix Pharmacology: Multiple Transporter Modulation at Serotonin Synapses
- 2026-09-07srcUS speeds up research into mind-altering drugs - including mysterious 'ibogaine'
- 2026-09-07srcMagnesium-ibogaine therapy in veterans with traumatic brain injuries
- 2026-09-07srcIbogaine and addiction in the animal model, a systematic review and meta-analysis
- 2026-09-07srcIbogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder
- 2026-09-07srcA case series of ibogaine toxicity reported to the United Kingdom National Poisons Information Service (NPIS) over a 10-year period
- 2026-09-07srcIbogaine for Opioid Use Disorder: An Unrecognized Risk
- 2026-09-07srcPsychedelic Therapy: A Primer for Primary Care Clinicians-Ibogaine
- 2026-09-07srcSafety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study
- 2026-09-07srcRare but relevant: Ibogaine and cardiovascular complications-prolonged QT interval and ventricular arrhythmias
- 2026-09-07srcUnderground ibogaine use for the treatment of substance use disorders: A qualitative analysis of subjective experiences
- 2026-09-07srcMechanisms of Antiaddictive Actions of Ibogaine
- 2026-09-07srcEffect of Ibogaine on the Various Sites of the NMDA Receptor Complex and Sigma Binding Sites in Rat Brain
- 2026-09-07srcIbogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures
- 2026-09-07srcThe pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients
- 2026-09-07srcFrom monotherapy to sequential models: An updated scoping review on ibogaine's role in treatment for psychiatric disorders
- 2026-09-07srcThe Ibogaine Experience Scale (IES): Development and psychometric properties of a multidimensional measure of ibogaine's subjective effects
- 2026-09-07srcAn analytical study of iboga alkaloids contained in Tabernanthe iboga-derived products offered by ibogaine treatment providers
- 2026-09-07srcIbogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence
- 2026-09-07src5-HT2A Receptor Knockout Mice Show Sex-Dependent Differences following Acute Noribogaine Administration
- 2026-09-07srcThe anti-addiction drug ibogaine and the heart: a delicate relation
- 2026-09-07srcIndole Alkaloids as Biased Opioid Receptor Modulators
- 2026-09-07srcA dose-response study of ibogaine-induced neuropathology in the rat cerebellum
- 2026-09-07srcDegeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline
- 2026-09-07srcIbogaine neurotoxicity: a re-evaluation
- 2026-09-07srcThe olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells
- 2026-09-07srcMedication development of ibogaine as a pharmacotherapy for drug dependence
- 2026-09-07srcIboga Conservation
- 2026-09-07srcIbogaine: Legal Status by Country (2026 Guide)
- 2026-09-07srcTabernanthe iboga Baill. - Plants of the World Online
- 2026-09-07srcIbogaine Legislation - State-by-State Tracker
- 2026-09-04issueIssued emergency
- 2026-09-04issueIssued info_card
- 2026-09-04issueIssued notice
- 2026-06-04proposal18 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
- 2026-06-04publicationPublication — backfill
- 2026-05-14revisionRevision 2
- 2026-05-14genGeneration — pipeline-v5 · with 1 morepipeline-v5
- 2026-05-14rungeneration run
- 2026-03-17importImported from Curiosity v1
- 2026-03-17publicationPublication — backfill
- 2026-03-17revisionRevision 1
The same entries, as forms: six forms.